Syed Ehtaishamul Haque
Overview
Explore the profile of Syed Ehtaishamul Haque including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
491
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Akram W, Najmi A, Haque S
J Mol Histol
. 2024 Nov;
56(1):3.
PMID: 39602021
Background: Cyclophosphamide (CP)-induced hepatotoxicity is a significant problem in clinical settings. This study aimed to evaluate the protective effect of levocabastine (LEV) on CP-induced hepatotoxicity in Swiss albino mice. Methods...
2.
Bhat F, Khan S, Khan A, Haque S, Akhtar M, Najmi A
Life Sci
. 2024 Nov;
358:123170.
PMID: 39490523
Aims: This review aims to elucidate the bidirectional relationship between heart failure and cancer by identifying their common and reciprocal risk factors. It seeks to provide a comprehensive understanding of...
3.
Khan A, Sharma S, Das A, Alam M, Syed M, Haque S
Iran J Basic Med Sci
. 2024 Feb;
27(3):326-334.
PMID: 38333757
Objectives: Neurological disorders are the world's most distressing problem. The adverse effects of current medications continue to compel scientists to seek safer, more effective, and economically affordable alternatives. In this...
4.
Akram W, Najmi A, Alam M, Haque S
Toxicol Appl Pharmacol
. 2024 Jan;
483:116838.
PMID: 38278497
Cyclophosphamide (CP), although a potent anti-cancer drug, causes cardiotoxicity as a side effect that limits its use. Hence, a specific medicine that can lower cardiotoxicity and be utilised as an...
5.
Iqubal A, Najmi A, Md S, Alkreathy H, Ali J, Syed M, et al.
Drug Deliv
. 2023 Aug;
30(1):2241661.
PMID: 37559381
Cyclophosphamide (CP) is one of the most extensively used antineoplastic drug, but the nephrotoxicity caused by this drug is a major limiting factor for its use. Nerolidol (NERO) is a...
6.
Sharma S, Iqubal A, Khan V, Sharma K, Najmi A, Haque S
Iran J Basic Med Sci
. 2023 Apr;
26(5):517-525.
PMID: 37051097
Objectives: Cardiovascular diseases are widespread across the globe, and heart failure (HF) accounts for the majority of heart-associated deaths. Target-based drug therapy is much needed for the management of heart...
7.
Ahmad Sheikh K, Iqubal A, Alam M, Akhter M, Ahmed Khan M, Haque S, et al.
Curr Med Chem
. 2023 Jan;
31(2):152-207.
PMID: 36718063
Cancer bears a significant share of global mortality. The enzyme Lysine Specific Demethylase 1 (LSD1, also known as KDM1A), since its discovery in 2004, has captured the attention of cancer...
8.
Nabi S, Bhandari U, Haque S
Iran J Basic Med Sci
. 2022 Aug;
25(7):827-841.
PMID: 36033946
Objectives: Inflammation is the major progenitor of obesity and associated metabolic disorders. The current study investigated the modulatory role of saroglitazar on adipocyte dysfunction and associated inflammation in monosodium glutamate...
9.
Sharma B, Satija G, Madan A, Garg M, Alam M, Shaquiquzzaman M, et al.
Inflammation
. 2022 Aug;
46(1):56-87.
PMID: 36006570
Alzheimer's disease (AD) is one of the most prevalent neurodegenerative disorders. The etiology and pathology of AD are complicated, variable, and yet to be completely discovered. However, the involvement of...
10.
Khan A, Iqubal A, Wasim M, Syed M, Haque S
Clin Exp Pharmacol Physiol
. 2022 Jul;
49(11):1232-1245.
PMID: 35866379
Cardiovascular diseases are the most disturbing problems throughout the world. The side effects of existing drugs are continuously compelling the scientist to look for better options in terms of safety,...